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INTRODUCTION
Humans are exposed to foreign organisms through swallowing, 
penetration of the skin and inhalation. Depending on both the 
virulence factors at its disposal and the integrity of host defence 
system mechanisms, these organisms would cause disease[1]. 
The association of immune cells and cancer was established 
by Balkwill and Mantovani[2]. The immune system is known to 
dominate spontaneous tumour development and infection in-
flammation, which is common with individuals with chronic 
inflammation and certain gene mutations that encode immune 
modifiers – namely, cytokines, proteases and signal transduc-
tion proteins[3, 4]. Neoplastic microenvironments also favour 
polarised chronic pro-tumorigenic inflammatory states. Such 
individuals have impaired T-lymphocytes and activation of their 
immune cells upsets a crucial balance and promotes cancer 
development[4-6]. 
Cancer arises as a result of a multi-step process leading from 
the initial benign transformation of cells through to invasive, 
metastatic disease[7]. It is a deadly (insidious) disease that 
progresses slowly, originating from mutant DNA sequences that 
change the direction of crucial pathways regulating homeosta-
sis, cell survival and cell death. They are composed of multiple 
cell types, such as fibroblasts and epithelial cells, innate and 
adaptive immune cells, and cells that form blood and lymphatic 
vasculature, as well as specialised mesenchymal cell types 
that are unique to each tissue environment[6]. Fifteen percent 
of all human cancers are believed to be caused by infectious 
conditions[8]. Greater risk of cancer amongst individuals with 
frequent antibiotic regimens could be either because they are 
maintaining low-level chronic inflammation due to their natural 
immune defence mechanisms or because they fail to normalise 
their immune status following infection[6]. Aging and individual 
differences also play a role in cancer development among 
the general population[3]. The relationship between chronic 
immune activation and malignancy is associated with the de-
velopment of tumours such as the lymphomas seen in Human 
Immunodeficiency Virus (HIV) induced Acquired Immunodefi-
ciency Syndrome (AIDS), or Chronic Graft-versus-host disease 
(GVHD)[9]. This brief review will explore the interaction of the 
immune system and malignancy. 
THE IMMUNE SYSTEM
The immune system is an interaction of lymphoid organs, 
humoral cell factors and cytokines to form a network, which 
becomes activated when something is wrong with the host de-
fence[1]. The immune system can be classified into two arms, 
namely cell-mediated immunity and antibody-mediated immu-
nity depending on the speed and specificity of the reaction of 
the immune response[1, 6]. It comprises several cell types and 
mediators that interact with non-immune cells and each other. 
These interactions form complex and dynamic networks to en-
sure protection against foreign pathogens; at the same time they 
tolerate auto antigens[6].
Cell populations (macrophages, dendritic cells (DCs), natural 
killers (NK) cells, and neutrophils) play a major role in both 
innate and acquired immunity[10] (Figure 1). 
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Principally, cytotoxic T lymphocytes (CTL) and NK cells are 
effector cells which produce cellular immune response to 
cancer[11]. DCs are the key components to CTL i.e. (CD8+ T-
cells) responses to tumours. They constitute a family of antigen-
presenting cells (APC) defined by their morphology and their 
capacity to initiate primary immune responses[12]. The helper T 
(Th)-cells, or CD4+ T-cells, are the major regulator of virtually all 
immune system activities. These form a series of protein media-
tors called lymphokines, which act on other cells of the immune 
system and on bone marrow[11]. The immunological dysfunc-
tion associated with human cancer comprises changes within 
the immune network, including cytokine imbalance of Th1/Th2 
origin. Without an immune response the antigen-specific T-cells 
may enter a state of tolerance or apoptosis[13]. The components 
of the immune system, do not recognize or respond to defective 
genes, but recognise and respond to the abnormal proteins that 
the cancer-causing genes encode. The individual components 
of the immune system play a major role in cancer[11].
Innate Responses 
Innate immunity is a mechanism whereby cells defend the 
host from infection by other organisms in a non-specific way. 
It involves a large number of different cell populations, namely 
epithelial cells, monocytes, macrophages, DCs, polymorpho-
nuclear leucocytes (PMN), NK cells, and various lymphocyte 
subpopulations (e.g. CD5-positive B-lymphocytes and gamma 
/ delta (gd) T-lymphocytes), which bridge the division between 
innate and acquired immunity[14]. Two further families of mol-
ecules play major roles in acquired immunity: major histocom-
patibility complex (MHC) gene products and cytokines. They 
provide an essential link for cell-to-cell communication and 
components of the acquired (as well as the innate) immune 
response[15].
Cytokine formation, release, and target interactions form an 
important arm of the cellular response in growth, repair, and 
cell proliferation. Cytokines can amplify the on-going immune 
response by up-regulating the expression of HLA (human leu-
kocyte antigen) and co-stimulatory molecules such as B7 on pa-
renchyma cells and APC[11]. They also function in the activation 
of macrophages, other inflammatory cells and the production 
of antibodies by stimulated T-cells. A product of the comple-
ment cascade strongly activates phagocytosis by neutrophils 
and macrophages, which engulf non-self-proteins. This type 
of cellular event is called antibody-dependent cell-mediated 
cytotoxicity (ADCC), and has the advantage of enhancing T-
cell activity[16]. The specificity of immune response resides in 
selective clonal proliferation of lymphocytes. NK cells form a 
line of defence against host cells that are stressed or cancerous. 
They express surface receptors that receive signals from the en-
vironment and determine their response to foreign or malignant 
cells by producing effector molecules. They can both directly 
suppress tumour growth and convey important information to 
the rest of the immune system[17]. When tissue homeostasis is 
disturbed, macrophages and mast cells immediately release sol-
uble mediators, such as cytokines, chemokine’s, matrix remod-
elling proteases, reactive oxygen species (ROS), and bioactive 
mediators such as histamine. The macrophages and mast cells 
also induce mobilisation and infiltration of additional leuco-
cyte into damaged tissue (inflammation), and activate vascular 
and fibroblast responses. This leads to elimination of invading 
organisms and initiation of local tissue repair, which resolves 
once the ‘wound’, is healed[18]. 
DCs take up foreign antigens, and migrate to lymphoid organs, 
where they present their antigens to adaptive immune cells. 
They play a key role between innate and adaptive immunity 
and rapidly respond to tissue injury without previous memory 
or antigenic specificity[6]. DCs can then present the tumour 
antigens on their surface, lodged within MHC molecules and 
activate T-cells. Once the T-cells are activated, they are capable 
of recognising and destroying antigen-expressing tumour cells. 
Antigen uptake receptors on dendritic cells provide efficient 
limitation of antigen specific adaptive immunity[19]. Innate im-
mune responses are induced by pattern-associated pathogens 
Figure 1: The relationship between innate and acquired immune systems. DCs are important in both innate 
and acquired immunity responding to tissue injury. DCs activate T-cells, recognize and destroy antigen-
expressing tumour cells. Innate responses are induced by pathogens, recognized by toll-like receptors on 
macrophages. Cytokines participate in cancer development .cell proliferation and survival is regulated by 
TNF-α. Response to T and B-Lymphocytes comes as a result of exposure. Th cells regulate the immune 
activities. Adapted from Kaisho, 2010.
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(e.g., lipopolysaccharide (LPS), double-stranded (ds) RNA, CpG 
DNA). These pathogens are recognised by toll-like receptors on 
macrophages[20] and by the natural killer cell surface receptors, 
NKG2D and other NKp receptor ligands expressed on infected 
cells[20].
Cancer development and innate immune responses
Innate immune cells have huge capacity to produce cytokines, 
chemokines, metalloproteinases, ROS, histamine and other 
bioactive mediators for cell survival which enables them to 
participate in cancer development[22, 23]. Chemokines and their 
receptors are responsible for infiltration of lymphocytes into the 
tumour tissue[3]. Due to the ability for matrix metalloproteinases 
(MMPs) to regulate epithelial cell proliferation, angiogenesis, 
cancer development, tissue homeostasis and disease, it has 
been identified as a crucial immune cell-derived mediator[24, 
25]. During acute inflammation, tumour necrosis factor-alpha 
(TNF-α) another inflammatory cytokine is mobilised (Figure 2). 
TNF-α mediates cancer development by regulating the prolifer-
ation and survival of neoplastic cells. They also have an indirect 
effect on endothelial cells, fibroblast and immune cells present 
in tumour microenvironments[26]. If produced by the tumour 
microenvironments, TNF-α will activate the pro-inflammatory 
nuclear transcription factor-κB (NF-κB) dependent anti-apoptot-
ic pathway during the time at which the foci of pre-malignant 
hepatocytes develop into tumours. NF-κB has shown suscep-
tibility to inflammation-induced intestinal tumours. These pro-
inflammatory cytokines contribute in a paracrine fashion to 
neoplastic cell proliferation and increase survival of initiated or 
damaged epithelial cells[27]. 
The cytokines released in response to this tissue destruction 
can induce up-regulation of key genes thought to be necessary 
for malignant transformation of tissues which are chronically 
inflamed, thought to inhibit apoptosis, promote angiogenesis, 
modulate cellular adhesion, and induce pro-inflammatory me-
diators, in addition to further recruitment of other innate and 
adaptive cell types[28, 29]. Suppression of anti-tumour adaptive 
immune responses by chronically activated innate immune 
cells can indirectly contribute to cancer development by allow-
ing tumours to escape from immune surveillance[6].
Adaptive Responses
Adaptive immunity is the ability for lymphocytes to undergo 
massive expansion from time to time. These begin with selected 
binding of T and B-lymphocyte and expansion of these selected 
cells to fight an antigen or pathogen[30]. Primary adaptive im-
mune responses require direct interactions with mature APCs 
and a pro-inflammatory surrounding for antigen specific reac-
tions of T-lymphocytes and B-lymphocytes. These reactions re-
sult in larger responses upon subsequent exposure to the same 
antigen[6]. When these pathways are activated, they efficiently 
remove invading pathogens, damaged cells and extracellu-
lar matrix (ECM) normalising cell proliferation and cell death 
pathways. This will enable re-epithelialisation and new ECM 
synthesis[6]. 
Adaptive immunity and cancer
The role of adaptive immune cells in cancer development is still 
debatable. The relative risk (RR) of cancer varies depending on 
the organ site and cancer origin. In cases of infection by onco-
genic viruses, such as hepatitis virus and human T-lymphotropic 
virus type 1 (HTLV-1), viral antigen presentation by HLA class 
I and II molecules to T-cells, and subsequent T-cell mediated 
cytotoxicity and cytokine production, are also key elements 
in the control of infection[3]. The adaptive immune system can 
also differentially regulate cancer development within the same 
epithelial microenvironment, as a function of varied initiation. 
Natural killer T (NKT) cells have also been reported in cancer 
development. NK cell recognition is mediated by the opposing 
Figure 2: Cancer could develop from chronic inflammatory conditions in a series of processes: Pro-
inflammatory cytokines and angiogenic factors enhance COX-2 and cyclo-oxygenase induction. NF-κβ also 
increases proliferation and survival. Malignancy results from pre-carcinogenic exposures leading to alteration 
of the micro-environment of the affected tissue. cAMP (cyclic Adenosine monophosphate); PI3K (phosphati-
dylinositol-3-kinase); IL-1β (interleukin-1β); TNF-α (tumour necrosis factor-α); NF-κβ (nuclear factor-κβ); 
COX-2 (cyclo-oxygenase-2); TGF-β (transforming growth factor-β); VEGF (vascular endothelial growth factor); 
IGF-I (insulin-like growth factor-I); MIP (macrophage inhibitory factor); PGE2 (prostaglandin-E2).  
(Adapted from Bryne and Dalgleish, 2001)[39].
52  www.smltsa.org.za  |  ISSN 1011 5528
Volume 26 No. 2  |  December 2012Medical Technology SA
effects of two different types of NK receptors: activation and 
inhibitory receptors. The activation receptors recognise stress-
induced ligands that are expressed on the target cell, and then 
transmit intracellular signals that initiate cytotoxicity[31]. The in-
hibitory receptors recognise cell-surface MHC class I molecules 
and generate counter-activating signals that block the induction 
of cytotoxicity. NK cells can also influence subsequent adaptive 
immune responses by releasing cytokines and chemokines that 
induce growth and differentiation of various immune cells[3]. 
They express certain NK cell markers and recognize glycolipid 
ligands presented by the MHC class I like molecule, cluster of 
differentiation 1 (CD1d)[32, 33]. 
Ironically, the influence of NKT cells during cancer development 
is probably a consequence of their inherent capacity to produce 
both pro-inflammatory Th1 cytokines and anti-inflammatory 
Th2 cytokines; therefore, the nature and balance of surround-
ing stimuli might determine which type of NKT cell induced 
T-helper response dominates and contributes to malignant out-
comes. CD4+ and CD8+ T-cells are important modulators of 
such tissue-damaging B-lymphocyte responses[34, 35]. Adaptive 
immunity has a crucial role in regulating and activating innate 
immune cells in affected tissues such as immunoglobulin depo-
sition which contributes to chronic inflammation and disease 
pathogenesis[36]. 
CHRONIC INFLAMMATION, INFECTION AND CANCER 
Inflammation is a process of responding to trauma usually 
caused by microbial infection. This process occurs in a se-
quence whereby various soluble factors and infiltrating cells, 
such as lymphocytes and leukocytes, are involved interacting 
with each other in different stages. This involves recognition of 
tissue penetration by pathogens or tissue injury, infiltration of 
lymphocytes, eradication of pathogens and killing of infected 
cells, liquefaction of surrounding tissue to prevent microbial 
metastasis and finally healing of damaged tissue[37]. 
Persistently activated immune cells usually characterise chronic 
infection through tissue destruction and repair, due to either ir-
removable injurious stimuli or a dysfunction in any component 
of the normal inflammatory response with sources of chronic 
inflammation. This includes infectious agents: basically physi-
cal and chemical agents such as environmental exposures and 
dietary carcinogens, sustained wounds and gastric fluids[38]. 
Chronic inflammation, arising as a result of chronic exposure to 
a non-infective irritant may also be associated with the develop-
ment of malignant disease[39]. This occurs when tissue home-
ostasis is seriously disturbed by failing to engage or disengage 
an arm of the immune system which allows the entry of im-
mune cells. Chronically activated myeloid suppressor cells and 
regulatory T-cells found in the circulation accumulate, initiating 
destruction within the tissues. Such destruction can result in 
excessive tissue remodelling, loss of tissue architecture protein 
and DNA alterations which may be due to oxidative stress, and, 
under certain circumstances, alters interactions between innate 
and adaptive immune cells. This alteration expresses oncogenes 
leading to increased risk of cancer development[6, 40, 41]. How 
long and strongly inflammation will continue after pathogen 
infection will depend mainly on the immunological features of 
the initial response. Cell proliferation does not by itself induce 
cancer but certain growth and survival factors enriched at sites 
of inflammation do. 
Once tissue trauma has healed, the inflammation associated 
with cell proliferation required for tissue-regeneration ends. The 
cytokine cascade plays an important role in speeding as well as 
suppression of the immune response to pathogens. When initi-
ated cells at sites of persistent inflammation continue to prolifer-
ate, they interact with inflammatory cells and growth factors 
such as TNF-α, a crucial step in carcinogenesis. In fact, many 
cancers are thought to be associated with inflammation caused 
by immunologically uncontrolled infections[42]. Among many 
cancers in which inflammation is considered to be involved, 
some may also be associated with production of carcinogenic 
proteins by infected microbes. Some examples are oncopro-
teins CagA by Helicobacter. pylori in gastric cancer and onco-
proteins X by hepatitis B virus (HBV)[43]. 
HLA molecules play a vital role in the recognition of antigens 
derived from carcinogenic proteins that have the potential to 
transform cells infected with these microbes, ensuring surveil-
lance of transformed cells[44, 45]. Coussens and Werb[46] found 
that persistent inflammation itself has carcinogenic activity. 
The inflammatory component of tumours with the surrounding 
stroma, has been found to contain many types of inflammatory 
cells, including mononuclear cells such as tumour associated 
macrophages, DCs, eosinophils, mast cells, and lymphocytes[47, 
48]. Several chronic infections known to be associated with 
malignancy have established oncogenic properties which can 
change the transcriptome of cells due to genetic mutation[49, 50]. 
COX-2 leads to the production of inflammatory cytokines and 
prostaglandins which themselves may suppress cell mediated 
immune responses and promote angiogenesis, inhibit apopto-
sis, cell proliferation and motility[7]. Angiogenesis is associated 
in normal physiological processes such as wound healing and 
plays a key role in the development of early neoplastic le-
sions[51].
IMMUNE DIRECTED APOPTOSIS OF CANCER
T-lymphocytes play a major role in the destruction of tumour 
cells. The immune system identifies tumour cells as ‘‘non-self’’ 
by several mechanisms (Figure 3), including recruitment of 
programmed cell death receptors that cause apoptosis of these 
cells[52]. However, tumour cells neutralise the immune system 
by evading detection and thereby prevent an immune response. 
The sensitised T-cells can affect killing of tumour cells by means 
of the lymphokines that they release. When these lymphokines 
are released, they mobilise and activate B-cells through B-cell 
growth factors and B-cell differentiation factors[11]. Macrophag-
es and NK cells also exert tumour-killing effects through other 
mechanisms[53]. 
On the other hand cancer cells may stimulate the immune 
system to express blocking antibodies, which cannot activate 
complement. This also means that no C3a or C3b is formed. 
Complement forms part of the innate immune system, it is some-
times recruited and brought to work by the adaptive immune 
system. As the disease progresses, there is associated decrease 
in immunity which results in a progressive fall in response to all 
foreign antigens[11]. Tumour cell death induced by conventional 
treatments releases a host of tumour associated antigens (TAAs) 
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which induces tumour cell death in order to stimulate an antitu-
mour immune response. Both radiotherapy and chemotherapy 
have been assumed to antagonise any priming of the immune 
system, by inhibiting lymphocyte division and inducing lym-
phocyte death[54]. Tumour cell apoptosis induced by these treat-
ments is considered non-immunogenic[55].
ROLE OF LILI IN THE ACTIVATION OF THE IMMUNE SYS-
TEM TOWARDS INHIBITION OR REDUCTION OF CANCER 
DEVELOPMENT
LILI is a non-invasive form of treatment using low energy la-
sers. When these lasers are applied to tissue, they stimulate 
biological responses, photochemical and physical responses in 
photoreceptor molecules within the cell[56]. It has been shown 
to regulate the body’s immune response locally and consist-
ently. It impacts cytokine production and heat shock protein 
synthesis[57]. This response includes ATP production, control of 
ROS[58-60] and induction of transcription factors such as activa-
tion protein-1(AP-1), NF-κβ, etc.[61-63]. This redox process occurs 
through the release of ROS[64]. A series of cellular processes 
result from this response namely cell proliferation and migra-
tion, change of cytokine levels, growth factors, inflammatory 
mediators and gene up-regulation. It also leads to oxygenation 
in the tissues. 
These factors may either increase or decrease depending on the 
wavelength, dose and intensity of the light[65, 66]. This process 
has been known over the years to reduce pain, inflammation, 
promote wound healing, prevent cell damage, etc[67]. Immuno-
therapy could be another useful method of cancer treatment. 
It does not only destroy the initial tumour but sensitises the 
immune system to destroy every remaining tumour[68]. DCs, ac-
cumulated as a response to an inflammatory response, phago-
cytise the primary tumour cells, mature and present to the T-
lymphocytes. These lymphocytes become activated and attract 
the chemokines which then move to the site of the remaining 
tumour and destroy it.
CONCLUSION
Cancer and its environment represent a system of complex 
interacting factors which includes the immune response and 
cellular control pathways. Genes which have been rearranged 
send signals to T and B-lymphocytes express surface recep-
tors. The B-cells recognise a single antigenic site on a protein 
against which an antibody reacts on intact proteins. The T-cells 
recognise antigens degraded into peptides and form complexes 
with MHC molecules on the cell surface. Antigen specific rec-
ognition plus signals from co-stimulatory molecules causes an 
intracellular signalling cascade that influences transcription 
factors in the cell nucleus. These transcription factors influence 
the expression of various genes, cytokines and effectors leading 
to an immune response. The changes lead to the production 
of tumour antigens that are presented on MHC molecules and 
are recognised by the immune system as non-self. Some may 
be eradicated by the immune system by immune surveillance 
before they are clinically evident or through the combination of 
immune and conventional therapy. 
Malignant transformation is accompanied by mutations or al-
tered expression of oncogenes within the malignant cells. It is 
possible to say that imbalanced or altered adaptive-immune-
cell interactions represent underlying mechanisms that regulate 
the onset and/or maintenance of chronic inflammation that is 
associated with cancer development since Immunoglobulin G 
deposition is found in human pre-malignant and malignant tis-
sues. The occurrence of cancers, despite a functioning immune 
system, and the probable antigenic similarity of cancers to the 
normal tissue in which they originate, has led to doubt that the 
Figure 3: Innate and acquired immunity interplay against tumour cells. Natural Killer cells in the innate 
immune response CD 36, MHC class Ι chain-related (MIC) A/B respectively are receptors that can directly 
activate or inhibit innate immunity. Acquired immunity is activated after phagocytosis of tumour cells by an 
APC. MHC 1 and 11 antigenic molecules are made available to either CD8 odr CD4 T cells. Once activated, 
there is cytotoxicity and secretion of cytokines to initiate the immune response towards the tumour cells[53].
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immune system has a significant role in cancer development 
and progression[54].
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